drugset / Trial / NCT04473911
Haplo Peripheral Blood Sct In GVHD Prevention
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation. * GVHD is a condition in which cells from the donor's tissue attack the organs. * RGI-2001 is an investigational treatment
Timeline
- Start
- 2020-08-14
- Primary completion
- 2023-10-22
- Completion
- 2024-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RGI-7000 | Small molecule | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Melphalan | Small molecule | — | — |
| Background | Mycophenolate Mofetil | Small molecule | — | Oral |
| Background | Sirolimus | Small molecule | — | Oral |